Abstract
Background To date, there is no high throughput proteomic study in the context of Autosomal Dominant Alzheimer’s disease (ADAD). Here, we aimed to characterize early CSF proteome changes in ADAD and leverage them as potential biomarkers for disease monitoring and therapeutic strategies.
Methods We utilized Somascan® 7K assay to quantify protein levels in the CSF from 291 mutation carriers (MCs) and 185 non-carriers (NCs). We employed a multi-layer regression model to identify proteins with different pseudo-trajectories between MCs and NCs. We replicated the results using publicly available ADAD datasets as well as proteomic data from sporadic Alzheimer’s disease (sAD). To biologically contextualize the results, we performed network and pathway enrichment analyses. Machine learning was applied to create and validate predictive models.
Findings We identified 125 proteins with significantly different pseudo-trajectories between MCs and NCs. Twelve proteins showed changes even before the traditional AD biomarkers (Aβ42, tau, ptau). These 125 proteins belong to three different modules that are associated with age at onset: 1) early stage module associated with stress response, glutamate metabolism, and mitochondria damage; 2) the middle stage module, enriched in neuronal death and apoptosis; and 3) the presymptomatic stage module was characterized by changes in microglia, and cell-to-cell communication processes, indicating an attempt of rebuilding and establishing new connections to maintain functionality. Machine learning identified a subset of nine proteins that can differentiate MCs from NCs better than traditional AD biomarkers (AUC>0.89).
Interpretation Our findings comprehensively described early proteomic changes associated with ADAD and captured specific biological processes that happen in the early phases of the disease, fifteen to five years before clinical onset. We identified a small subset of proteins with the potentials to become therapy-monitoring biomarkers of ADAD MCs.
Funding Proteomic data generation was supported by NIH: RF1AG044546
Competing Interest Statement
Carlos Cruchaga has received research support from GSK and EISAI. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Carlos Cruchaga is a member of the advisory board of Circular Genomics and owns stocks in these companies. DP is an employee of GlaxoSmithKline (GSK) and holds stock in GSK. Johannes Levin reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Merck and Roche, consulting fees from Axon Neuroscience, EISAI and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent Pharmaceutical Composition and Methods of Use (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. Eric M. McDade reports received the research support: NIA (U01AG059798), Anonymous Foundation, GHR, Alzheimer Association, Eli Lilly Eisai, Hoffmann La-Roche; paid consulting: Eli Lilly, Alector, Alzamend, Sanofi, AstraZeneca, Hoffmann La-Roche, Grifols, Roche, Merck.
Funding Statement
This study was funded by NIH: RF1AG044546.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of Washington University School of Medicine in St. Louis approved the study with the IRB number 201109148, and research was performed in accordance with the approved protocols.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The individual-level data from DIAN cannot be publicly shared. Due the rarity of this disease it makes all the data identifiable. This has been corroborated with the IRB and confirmed with the NIH, thus the data cannot be shared in public repositories. However, data is available to approved investigators via data request through https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/.
The proteomics and individual-level genetic data obtained from the ADNI cohort can be requested through ADNI’s website (adni.loni.usc.edu) after access has been approved.
The proteomics and individual-level genetic data obtained from the Knight-ADRC can be requested through the NIAGADS website (ng00130).
The proteomics and individual-level genetic data obtained from Fundació ACE Alzheimer Center Barcelona can be requested through Fundacio ACE’s website (www.fundacioace.com).
